Analysis of Hydroxychloroquine Adverse Events Reported in the WHO Pharmacovigilance Database

被引:0
|
作者
Ahmed, Nehad J. [1 ]
Alshehri, Ahmed M. [1 ]
Almalki, Ziyad S. [1 ]
Alahmari, Abdullah K. [1 ]
机构
[1] Prince Sattam Bin Abdulaziz Univ, Coll Pharm, Dept Clin Pharm, Alkharj, Saudi Arabia
来源
LATIN AMERICAN JOURNAL OF PHARMACY | 2023年 / 42卷 / 01期
关键词
adverse events; hydroxychloroquine; parmacovigilance; vigibase; CHLOROQUINE;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The drug hydroxychloroquine has been in use for a very long time. It is most frequently used to prevent and cure malaria. Hydroxychloroquine has been linked to a number of side effects, with stomach pain being the most frequent. This study used the WHO pharmacovigilance database (VigiBase) for analysis of adverse events related to hydroxychloroquine use. Till 29 June 2022, 34649 reports about the adverse events of hydroxychloroquine were submitted to the WHO pharmacovigilance database (VigiBase). The most reported side effects were general disorders and administration site conditions (37.01%), skin and subcutaneous tissue disorders (21.37%), gastrointestinal disorders (18.53%), injury, poisoning, and procedural complications (16.15%), musculoskeletal and connective tissue disorders (12.71%), investigations (12.00%), nervous system disorders (10.84%), infections and infestations (8.49%), and eye disorders (8.24%). Even though reports of adverse events cannot pinpoint the cause, additional research into some cases might be necessary. Our findings demonstrate the importance of pharmacovigilance and the necessity to inform medical professionals about the safety of hydroxychloroquine.
引用
收藏
页码:25 / 30
页数:6
相关论文
共 50 条
  • [21] Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database
    Hoisnard, Lea
    Lebrun-Vignes, Benedicte
    Maury, Sebastien
    Mahevas, Matthieu
    El Karoui, Khalil
    Roy, Lydia
    Zarour, Anissa
    Michel, Marc
    Cohen, Jose L.
    Amiot, Aurelien
    Claudepierre, Pascal
    Wolkenstein, Pierre
    Grimbert, Philippe
    Sbidian, Emilie
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [22] Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database
    Hoisnard, L.
    Lebrun-Vignes, B.
    Maury, S.
    Mahevas, M.
    El Karoui, K.
    Roy, L.
    Zarour, A.
    Michel, M.
    Cohen, J. L.
    Amiot, A.
    Claudepierre, P.
    Wolkenstein, P.
    Grimbert, P.
    Sbidian, E.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 165 - 165
  • [23] Statistical and graphical approaches for disproportionality analysis of spontaneously-reported adverse events in pharmacovigilance
    Zink, Richard C.
    Huang Qin
    Zhang Lu-Yong
    Bao Wen-Jun
    CHINESE JOURNAL OF NATURAL MEDICINES, 2013, 11 (03) : 314 - 320
  • [24] Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database
    Léa Hoisnard
    Bénédicte Lebrun-Vignes
    Sébastien Maury
    Matthieu Mahevas
    Khalil El Karoui
    Lydia Roy
    Anissa Zarour
    Marc Michel
    José L. Cohen
    Aurélien Amiot
    Pascal Claudepierre
    Pierre Wolkenstein
    Philippe Grimbert
    Emilie Sbidian
    Scientific Reports, 12
  • [25] Comprehensive Analysis of Ixazomib-Induced Adverse Events Using the Japanese Pharmacovigilance Database
    Yamaoka, Kenta
    Fujiwara, Masaki
    Uchida, Mayako
    Uesawa, Yoshihiro
    Muroi, Nobuyuki
    Shimizu, Tadashi
    ONCOLOGY, 2022, 100 (07) : 413 - 418
  • [26] Ophthalmic adverse events under tofacitinib and baricitinib: Case analysis of the European Pharmacovigilance Database
    Hecquet, Sophie
    Rabier, Marie-Blanche Valnet
    Lepelley, Marion
    Verhoeven, Frank
    Delbosc, Bernard
    Avouac, Jerome
    Prati, Clement
    Gauthier, Anne-Sophie
    Wendling, Daniel
    JOINT BONE SPINE, 2023, 90 (01)
  • [27] Adverse drug reactions associated with ivermectin use for COVID-19 reported in the WHO's pharmacovigilance database
    Campillo, J.
    Faillie, J. L.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 101 - 101
  • [28] Association Between Major Cardiovascular Events and Esketamine: A Disproportionality Analysis in the WHO Pharmacovigilance Database
    De Laportaliere, Tanguy Taillefer
    Lepetit, Marianne
    Yrondi, Antoine
    Montastrue, Francois
    DRUG SAFETY, 2024, 47 (12) : 1314 - 1314
  • [29] Retrospective analysis of dermatologic adverse events associated with hydroxychloroquine reported to the US Food and Drug Administration
    Lipner, Shari R.
    Wang, Yu
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (05) : 1527 - 1529
  • [30] Synthetic cannabis: adverse events reported to the New Zealand Pharmacovigilance Centre
    Robson, Hunter
    Braund, Rhiannon
    Glass, Michelle
    Ashton, Janelle
    Tatley, Michael
    CLINICAL TOXICOLOGY, 2021, 59 (06) : 472 - 479